Gross Law Firm Raises Awareness of Pacira BioSciences Lawsuit Affecting Shareholders with Important Deadlines
The Gross Law Firm has recently issued an urgent notification to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX) about a current class action lawsuit. This notice aims to inform investors who purchased shares during a specific timeframe and encourages them to partake in the proceedings, particularly regarding the upcoming deadlines for involvement as lead plaintiffs.
The class period spans from August 2, 2023, to August 8, 2024. The crux of the allegations occurs after a troubling announcement on August 9, 2024, when Pacira revealed the results of its legal battle against eVenus concerning patent infringement. In a significant blow to the company, the court determined that Pacira's U.S. Patent No. 11,033,495—critical for one of its leading products, Exparel—was invalid. This patent constitutes approximately 80% of Pacira’s revenues, making its invalidation particularly damaging. Following this release, the company's stock experienced a staggering decline, plummeting from $22.36 a share to a low of $11.70, representing a decrease of over 47% in just one day.
Investors are urged to register their information promptly to not miss out on potential recovery. By signing up, shareholders who acquired shares of PCRX during the designated period will be included in a portfolio monitoring program, updating them on case developments. The deadline for those looking to be appointed as lead plaintiffs is fast approaching—March 14, 2025. Luckily, registration comes at no cost or obligation, making it easier for investors to engage without risk.
The Gross Law Firm prides itself on being a leading class action firm, advocating for investors who have fallen victim to misleading corporate practices. Their goal is to ensure that companies maintain ethical and responsible business conduct. The firm’s focus is not only on seeking recovery for current cases but also on fostering accountability in corporate citizenship. They understand that a firm’s misrepresentation or lack of critical information can unduly inflate the stock prices, ultimately harming investors.
It is critical for shareholders affected by these developments to act swiftly. They should ensure that they have registered their claims to secure their participation in the lawsuit. If you are a shareholder of Pacira BioSciences, visit their official notification page to register and stay informed. With the complexity of securities law, having legal representation can provide a strategic advantage.
For further inquiries, shareholders may reach out directly to The Gross Law Firm. Their offices are located at 15 West 38th Street, 12th floor, New York, NY, 10018, with the dedicated phone number 646-453-8903 and email contact available for any questions regarding the case.
The ongoing lawsuit against Pacira BioSciences is a pivotal moment for shareholders, emphasizing the importance of understanding patent rights and the company's legal landscape. By taking proactive steps, investors can potentially safeguard their interests during this challenging period.
Background of the Lawsuit
The class period spans from August 2, 2023, to August 8, 2024. The crux of the allegations occurs after a troubling announcement on August 9, 2024, when Pacira revealed the results of its legal battle against eVenus concerning patent infringement. In a significant blow to the company, the court determined that Pacira's U.S. Patent No. 11,033,495—critical for one of its leading products, Exparel—was invalid. This patent constitutes approximately 80% of Pacira’s revenues, making its invalidation particularly damaging. Following this release, the company's stock experienced a staggering decline, plummeting from $22.36 a share to a low of $11.70, representing a decrease of over 47% in just one day.
Importance of Registering
Investors are urged to register their information promptly to not miss out on potential recovery. By signing up, shareholders who acquired shares of PCRX during the designated period will be included in a portfolio monitoring program, updating them on case developments. The deadline for those looking to be appointed as lead plaintiffs is fast approaching—March 14, 2025. Luckily, registration comes at no cost or obligation, making it easier for investors to engage without risk.
Gross Law Firm's Commitment
The Gross Law Firm prides itself on being a leading class action firm, advocating for investors who have fallen victim to misleading corporate practices. Their goal is to ensure that companies maintain ethical and responsible business conduct. The firm’s focus is not only on seeking recovery for current cases but also on fostering accountability in corporate citizenship. They understand that a firm’s misrepresentation or lack of critical information can unduly inflate the stock prices, ultimately harming investors.
Action Steps for Shareholders
It is critical for shareholders affected by these developments to act swiftly. They should ensure that they have registered their claims to secure their participation in the lawsuit. If you are a shareholder of Pacira BioSciences, visit their official notification page to register and stay informed. With the complexity of securities law, having legal representation can provide a strategic advantage.
For further inquiries, shareholders may reach out directly to The Gross Law Firm. Their offices are located at 15 West 38th Street, 12th floor, New York, NY, 10018, with the dedicated phone number 646-453-8903 and email contact available for any questions regarding the case.
Conclusion
The ongoing lawsuit against Pacira BioSciences is a pivotal moment for shareholders, emphasizing the importance of understanding patent rights and the company's legal landscape. By taking proactive steps, investors can potentially safeguard their interests during this challenging period.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.